The United Parcel Service (UPS  ) is gearing up for the distribution of COVID-19 vaccines by increasing dry ice production and rolling out mobile freezers. The company is attempting to negate a shortage of dry ice as pharmaceutical firms prepare for the rollout of their vaccines.

A Coronavirus vaccine may finally be right around the corner as major pharmaceutical companies release promising trial results as they near the distribution stage. Moderna's (MRNA  ) vaccine was documented as having a 94.5% rate of effectiveness against the virus. The Pfizer (PFE  ) and BioNTech (BNTX  ) joint vaccine had an effectiveness rate of 95% as well. The demand for a vaccine, however, poses logistical concerns over the effective distribution of the vaccine.

UPS, at least, appears to be addressing these logistical concerns by ramping up production of dry ice as it prepares for the burden of shipping vaccines. According to a release by the company, UPS Healthcare is now capable of producing up to 1,200 lbs. of dry ice per hour. The dry ice will not only bolster UPS' ability to ship vaccines, but the company will also make the ice available for healthcare providers to store vaccines on-site.

"Enhancing our dry ice production capabilities increases our supply chain agility and reliability immensely when it comes to handling complex vaccines for our customers," says President of UPS Healthcare Wes Wheeler. "Healthcare facilities in Louisville, Dallas and Ontario will ensure we have the capability to produce dry ice to sufficiently pack and replenish shipments as needed to keep products viable and effective."

UPS is also partnering with Stirling Ultracold to produce ultra-low temperature freezers that will be distributed among smaller care facilities to serve as a better storage solution for vaccines.

"We are truly proud to partner with UPS in this critical effort. As the leading manufacturer of small and portable ULT devices, Stirling Ultracold freezers integrate well with UPS Healthcare logistics to provide complete cold-chain of custody for Covid-19 vaccines from the drug manufacturers to medical facilities," says Stirling CEO Dusty Tenney.